- ￥620 - 2200
- 善本生物
- 2934
- 2026年01月08日
- Western Blotting (WB), Flow Cytometry (FCM), Immunocytochemistry (IC)
- 兔
- Human
企业认证
相关产品推荐更多 >
KD-Validated Anti-FBXO21 Mouse Monoclonal Antibody
￥650KD-Validated Anti-EIF2AK2 Mouse Monoclonal Antibody #63730
￥650
Anti-Tissue Factor Rabbit Monoclonal Antibody #2300
￥620KD-Validated Anti-G-rich RNA sequence binding factor 1 Rabbit Monoclonal Antibody #63672
￥650Anti-FTCD Rabbit Monoclonal Antibody #2053
￥620
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 浓度：
Recommended Dilutions：Western Blotting (WB): 1:1,000-1:5,000 Flow Cytometry (FCM): 1:2,000 Immunocytochemistry (IC): 1:100-1:1,000
- 应用范围：
Western Blotting (WB), Flow Cytometry (FCM), Immunocytochemistry (IC)
- 宿主：
兔
- 适应物种：
Human
- 保质期：
One year
- 克隆性：
Rabbit mAb
- 保存条件：
Store at -20 °C for one year. Supplied in PBS (pH 7.4) containing 50% glycerol, and 0.02% sodium azide.
- 形态：
液体
- 亚型：
Rabbit IgG
- 免疫原：
A synthesized peptide derived from human FGFR1
- 规格：
20ul/50ul/100ul
| 规格： | 20ul | 产品价格： | ￥620.0 |
|---|---|---|---|
| 规格： | 50ul | 产品价格： | ￥1200.0 |
| 规格： | 100ul | 产品价格： | ￥2200.0 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
of action. The other five products function through alternative primary modes of action (blockade of growth factor–receptor interaction, receptor downmodulation and inhibition of signalling). Again, it should be noted that mAbs are not necessarily restricted
Chimerization of a Monoclonal Antibody for Treating Hodgkin's Lymphoma
Ber-H2 which recognizes the human CD30 molecule with high specificity and affinity (2 ). CD30, a member of the nerve growth factor (NGF) tumor necrosis factor receptor (TNFR) superfamily (3 ), is strongly expressed on the pathognomonic Hodgkin (H
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料
